Determination Of Lamotrigine Research Articles

Determination of lamotrigine in human plasma by HPLC-PDA. Application to forensic samples.

Therapeutic drug monitoring of plasma lamotrigine (LTG) has customarily been carried out in order to prevent some its adverse effects. For forensic purposes, determination of LTG in plasma is an useful tool in cases of accidental overdose or suicidal attempts. Currently, there are several analytical methods available including some based on LC tandem mass spectrometry techniques, but simple and accessible LC-UV methods still can be useful for the purpose. Here we report on a new high-performance liquid chromatography method for the determination of lamotrigine in human plasma which has been developed and validated including selectivity, sensitivity, accuracy, precision and recovery studies. Lamotrigine and the internal standard chloramphenicol were extracted from plasma using liquid-liquid extraction using small volumes of buffer and ethylacetate. Detection was monitored at 305.7 and 276.0nm for lamotrigine and chloramphenicol, respectively. The method was linear concentration dependence within the range of 0.1-10µg/ml, with a mean coefficient of correlation r = 0.993. The limit of detection (LOD) was 0.04µg/ml and the limit of quantification (LOQ) was 0.1µg/ml. Intra and interday precision values were lower than 9.0% at all concentrations studied. The intra and interday accuracy values ranged from - 7.6 to 10.1%. Recovery was found to be 98.9% or higher. The method here described was successfully applied to 11 postmortem blood samples received at the Forensic Sciences Institute of Santiago de Compostela (Spain). A new HPLC method for the determination of lamotrigine in human plasma was developed and validated. A liquid-liquid extraction using small volumes of buffer and ethylacetate was optimized. The proposed method is suitable for forensic toxicological analysis.

Fabrication of Au Nanoparticles Coated Metal Fiber for the Solid-Phase Microextraction and Determination of Lamotrigine in Complex Matrixes

A solid phase microextraction fiber (SPME) with gold nanoparticles coatings (AuNPs) was prepared based on stainless-steel fiber by chemical deposition. In order to greatly increase the specific surface area of the stainless-steel fiber, the porous fiber were formed by hydrofluoric acid treatment and aqua regia-dopamine treatment after AuNPs coating. Thus, the porous gold coated SPME with large specific surface area, strong bonding and controllable thickness were prepared. Scanning electron microscopy (SEM) and elements analysis were used to characterize. Under the optimized conditions, the prepared fibers exhibited good precision, wide linear ranges, acceptable recoveries, and low limits of detection for lamotrigine. The results verified that this novel coating was a promising sorbent for extraction and trace analysis of lamotrigine in complex matrixes.

Simultaneous Determination of Lamotrigine, Oxcarbazepine, Lacosamide, and Topiramate in Rat Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.

This study established an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to study the pharmacokinetics of four antiepileptic drugs, lamotrigine, oxcarbazepine, lacosamide, and topiramate, in rats after oral administration. The gradient elution was performed on a UPLC HSS T3 (2.1 mm × 100 mm, 1.8 μm) column with acetonitrile-0.1% formic acid as the mobile phase at a flow rate of 0.4 mL/min. Protein precipitation by acetonitrile was adopted for plasma sample pretreatment. Electrospray- (ESI-) positive/negative ion switching and multiple reaction monitoring (MRM) modes were adopted for ion quantitative determination of antiepileptic drugs. UPLC-MS/MS detection and Drug and Statistics (DAS) software fitting were performed to blood samples collected from rats after oral administration of lamotrigine, oxcarbazepine, lacosamide, and topiramate (5 mg/kg). All drugs examined showed linearity within 5–5000 ng/ml (R2 > 0.9987), the intraday accuracy was within 92%–108%, and the interday accuracy was within 93%–109%. The relative standard deviations (RSD) of intraday and interday were less than 15%. The matrix effect was within 91%–105%, and the recovery was better than 88%. The established UPLC-MS/MS method was successfully applied to the pharmacokinetic study of lamotrigine, oxcarbazepine, lacosamide, and topiramate in rats.

New, simple and express determination of lamotrigine in tablets by using diazole red 2J

Epilepsy is considered one of the most common chronic neurological diseases among humans. Lamotrigine is an effective new-generation anticonvulsant, which is widely introduced to the pharmaceutical market by various drug manufacturers. That is why the urgent aim for pharmaceutical analysis is developing of high precision, valid, accessible and quantitative methods for lamotrigine in pharmaceuticals.
 The aim of the work is to study the optimal conditions for the reaction between lamotrigine and diazole red 2J, to define the coefficients of stoichiometric relationships in the “pharmaceutical substance – reagent” system and to develop a valid, sensitive and easy-to-follow technique for the quantitative determination of lamotrigine in pharmaceutical forms.
 Material and methods. As reagent and solvent, diazole red 2J of AR grade and acetone of AR grade were used. Analytical equipment: Specord 200 spectrophotometer, ABT-120-5DM electronic scales, Elmasonic E 60H ultrasonic bath and measuring glassware of A class.
 Results. A new spectrophotometric method for the quantitative determination of lamotrigine in four pharmaceutical formulations based on interaction with diazole red 2J in acetone medium has been developed. The proposed method is valid according to such validation characteristics as linearity, precision, intra-laboratory precision, accuracy, application range and robustness. The subordination to Behr's law is in the range of concentrations of 2.20–3.36 mg/100 ml. The LOD and LOQ values based on the values of the calibration line were 0.00450 % and 0.0138 % respectively. It was found that the studied coloured solutions are stable for at least 60 min and fluctuations in the amount of added red diazole 2J solution within ±10 % do not significantly affect the value of optical density. The coefficients of stoichiometric ratios between the components of the “lamotrigine – diazole red 2J” reaction mixture were defined by three methods and are 1:1. The predicted complete uncertainty of the results of analysis for quantitative determination of lamotrigine in the pharmaceutical form (2.2 %) does not exceed the maximum allowable uncertainty for the technique (3.2 %) and meets the SPhU requirements.
 Conclusions. According to the experimental data, the technique can be correctly reproduced and it is suitable for using in laboratories of the State Inspection for Quality Control of Medicines and QCD of the chemicopharmaceutical enterprises

Development of Analytical Profile of Lamotrigine and its API Formulation

Objective: The objective of this review is to put a light on the development of lamotrigine and its active pharmaceutical ingredients formulation with proper demonstration.
 Method: In the present work, one of the most imperative spectrophotometric method which is RP-HPLC method has been developed for the quantitative estimation of lamotrigine in bulk and pharmaceutical formulations.
 UV spectrophotometric method which involves the determination of Lamotrigine in bulk and in bulk drug and pharmaceutical formulation has maximum absorption at 307.5nm in methanol. It obeys Beer’s and Lambert’s law in the concentration range of 5-45 µg/ml.
 A rapid and sensitive RP- HPLC Method with UV detection (270 nm) for routine analysis of Lamotrigine formulation was developed. Chromatography was performed with mobile phase containing a mixture of methanol and Phosphate buffer (65:35v/v) with flow rate 1.0 ml/min. In the range of 20-100 µg/ml, the linearity of lamotrigine shows a correlation co-efficient of 0.9998. The proposed method was validated by determining sensitivity and system suitability parameters.

Determination of lamotrigine by fluorescence quenching of N-doped graphene quantum dots after its solid-phase extraction using magnetic graphene oxide

A sensitive fluorescent nanoprobe is reported for the determination of lamotrigine after its preconcentration by magnetic graphene oxide nanocomposite. The fluorescent nanoprobe is based on the quenching effect of lamotrigine on the nitrogen graphene quantum dots fluorescence at 440 nm, through strong hydrogen bonding. Under optimum conditions, the quenching fluorescent intensity of nitrogen graphene quantum dots shows linearity with the lamotrigine concentration in the range of 2.0–45.0 µg L−1, limits of detection (LOD), and quantification of 0.39 and 1.28 µg L−1 respectively. The parameters affecting the extraction and determination of lamotrigine were optimized via the central composite design (CCD) and one at the time method, respectively. The developed method was successfully employed for the extraction and quantification of lamotrigine in biological samples.

A Review on Analytical Method for Determination of Lamotrigine in Bulk and Pharmaceutical Dosage Form

Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy & bipolar disorder/major affective disorder (manic depression). Lamotrigine is and antiepileptic drug of phenyltriazine class. For epilepsy it is used to treat the partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with the Lennox-Gastuat syndrome and are chemically unrelated to the other anticonvulsants. Lamotrigine is a phenyltriazine that has comparatively few side-effects and it does not requires blood monitoring/observance in monotherapy. It additionally acts as a mood stabilizer. Common side-effects of lamotrigine include, nausea, sleepiness, headache, vomiting, trouble/bother with co-ordination and rash. Serious side-effects include in, lack of red blood cells, accumulated in risk of suicide, Stevens-Johnson syndrome and allergy. It issues that use of lamotrigine throughout pregnancy or breastfeeding it’s going to lead/result in harm/damage.

Development and validation of an improved HPLC-UV method for simultaneous determination of lamotrigine and oxcarbazepine and its active metabolite 10,11-dihydro-10-hydroxycarbazepine in human blood plasma and comparison with an UHPLC-MS/MS method

Lamotrigine (LTG) and oxcarbazepine (OXC) are first-line drugs for epilepsy treatment. Their large pharmacokinetics variabilities and relations between efficacy and toxicity and blood plasma concentration require routine monitoring for dose adjustment. In this study, we developed and validated a simple, accurate, and reliable method for simultaneous determination of LTG, OXC and 10,11-dihydro-10-hydroxycarbazepine (MHD) in human blood plasma by high-performance liquid chromatography-ultraviolet detection (HPLC-UV) with a simple one-step protein precipitation using methanol (1% acetic acid) and 15 min elution time under isocratic elution at 1 mL/min. Calibration range was 2.4 to 120 mg/L for LTG, OXC, and MHD. The intra-day and inter-day bias were − 8.84 to 4.18%, and the imprecision was less than 8.08% for all analytes. The internal standard (fluconazole) normalized recovery was 96.30 to 107.69% for LTG, 98.51 to 111.04% for MHD, and 95.04 to 109.86% for OXC. A total of 186 LTG samples and 25 MHD samples were used to evaluate the agreement between HPLC-UV and ultra-performance liquid chromatography-mass spectrometry (UHPLC-MS/MS) by Passing-Bablok regression and Bland-Altman plot. The mean bias and the 95% limits of agreement (95% LOA) of the two measurements were 0.575 mg/L and − 1.238 to 2.387 mg/L for LTG (n = 186) and − 1.222 mg/L and − 8.271 to 5.827 mg/L for MHD (n = 25), which indicated the UV method was comparable with the MS method for LTG and MHD analysis.

Determination of lamotrigine in human plasma using liquid chromatography-tandem mass spectrometry.

AimLamotrigine (LTG) is a widely used anti‐epileptic drug that is administered to avoid seizures and to maintain seizure‐free status. However, several factors reportedly cause individual differences of plasma LTG levels, and the therapeutic target range of LTG varies between individuals. Thus, to optimize effective doses of LTG, we developed a rapid and simple method for determining plasma LTG concentrations.MethodsLamotrigine and the internal standard papaverine were extracted from human plasma using solid‐phase extraction. After filtration, 5‐μL aliquots of final samples were injected into the liquid chromatography‐tandem mass spectrometry instrument and LTG and internal standard were separated using a Cadenza CD‐C18 column (100 × 2 mm, 3 μm) with 0.1% formic acid in water/acetonitrile (2/1, v/v).ResultsThe calibration curve was linear from 0.2 to 5.0 μg/mL, and assessments of recovery, intra‐ and inter‐day precision and accuracy, matrix effects, freeze and thaw stability, and long‐term stability demonstrated good reproducibility. Retention times of LTG and internal standard were 1.6 and 2.0 minutes, respectively, and the total run time was 3.5 minutes for each sample.ConclusionWe developed a rapid and simple method for determining plasma LTG concentrations. The present novel system could be used to inform LTG dose adjustments for individual patients.

An easy-to-use liquid chromatography assay for the analysis of lamotrigine in rat plasma and brain samples using microextraction by packed sorbent: Application to a pharmacokinetic study.

A simple and rapid high-performance liquid chromatography method with diode-array detection (HPLC-DAD) using microextraction by packed sorbent (MEPS) during the sample preparation step was developed and validated to quantify lamotrigine (LTG) in rat plasma and brain samples. MEPS variables such as pH, number of draw-eject cycles, and washing and desorption conditions were optimized. The chromatographic resolution of LTG and chloramphenicol, used as internal standard (IS), was accomplished in less than 5min on a C18 column, at 35°C, using an isocratic elution with acetonitrile (13%), methanol (13%) and water-triethylamine (99.7:0.3, v/v; pH 6.0) pumped at a flow rate of 1mL/min. Detection was performed at 215nm. Calibration curves were linear over the range of 0.1-20μg/mL (r2≥0.9947) for LTG in both rat plasma and brain homogenate samples. The intra and interday imprecision did not exceed 8.6% and the intra and interday inaccuracy ranged from -8.1 to 13.5%. LTG was extracted from rat plasma and brain homogenate samples with an average absolute recovery ranging from 68.0 to 86.7%, and its stability was demonstrated in the assayed conditions. No interferences were observed at the retention times of the analyte (LTG) and IS. To the best of our knowledge, this is the first bioanalytical assay that uses MEPS procedure for the determination of LTG not only in rat plasma but also in tissue (brain) samples. This novel method was successfully applied to a preliminary pharmacokinetic study in rats and it seems to be a cost-effective tool to support non-clinical pharmacokinetic-based studies involving LTG treatment.

Spectrophotometric Estimation of Lamotrigine in Tablets

Simple and accurate spectrophotometric methods have been developed for the determination of lamotrigine in tablet formulation. The method A was based on the diazotization of lamotrigine followed by coupling with 4-(dimethylamino)benzaldehyde in acid medium to give greenish yellow product with a λmax of 410 nm. The method B also was based on the diazotization of drug and conversion of phenol into nitrosophenol with excess nitrous acid in acid medium to give brown color with a λmax of 448 nm. Thus, methods A and B were used to determine lamotrigine in the range of 1-10 μg/ml and 2.5-12 μg/ml, respectively in the final measured solution. There was no interference from the ingredients commonly found in lamotrigine tablets with these methods. The results compared favorably with those of reported methods and related analytical parameters were calculated.

STABILITY – INDICATING SPECTROPHOTOMETRIC METHODS FOR DETERMINATION OF LAMOTRIGINE IN PURE FORM AND PHARMACEUTICAL PREPARATIONS

Three simple, sensitive, accurate, and precise methods were developed for determination of lamotrigine (LTG) in bulk powder and pharmaceutical preparations. The first method depends on charge transfer complexing of LTG with chloranilic acid (CA) as will as with 2,3-Dichloro-5,6-Dicyano-1,4-benzoquinone (DDQ) to produce purple color measured at 520 and 588 nm for CA and DDQ respectively. Beer’s low was obeyed in the range of 25 –200 and 6- 42 µg ml-1 with LOD of 3.06 and 0.498 µg ml-1 and LOQ of 10.19 and 1.66 µg ml-1 respectively. The second method depends on ion pairing of LTG with bromothymol blue (BTB), bromophenol blue (BPB) and bromocresol green (BCG) to produce red colored complexes measured at 419, 417 and 417 nm for the three reagents respectively. Beer’s low was obeyed in the range of 2 – 12 µg ml-1 for all reagents. LOD was found to be 0.56, 0.18 and 0.13 µg ml-1 while LOQ was 1.66, 1.86 and 0.53 respectively. The third method is the adopting of the first derivative spectrophotometry at 291 nm for direct determination of lamotrigine in presence of its degradation product. A linear relationship between peak height and drug concentration was obtained in the range of 10 – 70 µg ml-1.LOD and LOQ were found to be 0.68 and 2.26 µg ml-1 respectively. The percent recoveries ± RSD% of these methods were 99.52-100.36 ± 0.78-1.34, 99.65-100.48 + 0.85-1.38, and 99.62-100.26 ± 1.17-1.22 % respectively. The obtained results were compared with those of the reported method and no significant difference was observed regarding accuracy and precision

Determination of lamotrigine by using molecularly imprinted polymer–carbon paste electrode

By using a molecularly imprinted polymer (MIP) as a recognition element, construction of a high selective voltammetric sensor for lamotrigine (LTG) was performed. A LTG selective MIP and a non-imprinted polymer (NIP) were synthesized and then incorporated in the carbon paste (CP) electrodes. The sensor was applied for LTG determination using differential pulse voltammetric (DPV) method. The MIP–CP electrode showed very high recognition ability in comparison to NIP–CPE. Some parameters affecting the sensor response were optimized and then the calibration curve was plotted. Two dynamic linear ranges of 0.8–25 and 25–400nM were obtained. The detection limit of the sensor was calculated as 0.21nM. This sensor was used successfully for LTG determination in pharmaceutical preparations.

DETERMINATION OF LAMOTRIGINE IN TABLETS USING HPTLC, HPLC, AND DERIVATIVE SPECTROPHOTOMETRY METHODS

The determination of lamotrigine in tablets using high-performance thin-layer chromatography (HPTLC), high-performance liquid chromatography (HPLC), as well as direct, first, second, and third derivative ultraviolet spectrophotometry methods are described. HPTLC method was performed using silica plates, a mobile phase composed of toluene:acetone:ammonia (3:7:0.5, v/v/v), and a densitometric detection at 312 nm. Moreover, quantification was achieved in the concentration range of 0.25–10.0 µg/spot and with good precision (RSD = 2.19%) and recovery (97.92%), using a nonlinear calibration curve by fitting to y = a + blnx. HPLC method was performed using a Luna C18 column and isocratic elution mode with a mobile phase composed of methanol: phosphate buffer (25:75, v/v) and delivered at a flow rate 1.2 mL/min. Proposed HPLC method provided good results of precision (RSD = 1.86%) and recovery (101.51%) in the concentration range of 0.25–7.5 µg/mL using linear y = a + bx regression analysis. For the UV-derivative spectrophotometry method, all derivatives and wavelengths studied proved accurate linearity, precision (RSD = 0.96–1.87%), and recovery (96.74–101.90%). Moreover, no interference was found from tablet excipients at the selected wavelength and assay procedures. The developed methods were found to be validated and showed good precision and reproducibility.

Spectrophotometric Studies of Lamotrigine Charge Transfer Complexes:Synthesis and Characterization

Charge transfer complexes of lamotrigine with 7,7,8,8-tetracyanoquinodimethane, bromothymol blue and picric acid have been investigated by spectrophotometric method. Optimum conditions for the reactions and validation data is reported. Resulting complexes absorb at 394, 404 and 374 nm in the Beer's law range of 0.15-15, 0.25- 10 and 3.0-18 µg mL -1 with correlation coefficient greater than 0.998 in each case and detection limits 45, 47 and 57 µg mL -1 respectively. The data are discussed in terms of molar absorptivity, association constant and Gibb's free energy. Spectral characteristics including oscillator's strength, dipole moment, ionization potential, energy of complexes and resonance energy have been determined. Benesi-Hildebrand plots for each complex have been constructed. The proposed method was applied successfully for the determination of lamotrigine in pharmaceutical formulations. Satisfactory recovery values suggested that the method is reliable for the determination of lamotrigine in pharmaceutical formulations without interference of excipients. Further, solid charge transfer complexes were synthesized and characterized by IR and 1 H NMR spectroscopy.

HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHY: A WORTHY TECHNIQUE FOR THE DETERMINATION OF LAMOTRIGINE IN TABLETS AND HUMAN PLASMA

A rapid, stability indicating hydrophilic interaction liquid chromatography (HILIC) method was developed for the determination of lamotrigine and its induced alkaline degradation product. The separation was performed on an unmodified silica column adopting UV detection at 290 nm with flow rate of 1.5 mL min−1. The mobile phase consisted of a mixture of acetonitrile:ammonium formate 0.01 M (85: 15, v/v) and the pH was adjusted at 5.0. The method showed good linearity in the range of 0.5-10 µg mL−1 with lower limit of detection (LOD) 0.1 µg mL−1 and limit of quantification (LOQ) 0.5 µg mL−1, respectively. The proposed method was applied to tablets assay and was further extended to the in vitro and in vivo determination of the drug in spiked and real human plasma. The mean percentage recoveries were 100.32 ± 2.59 (n = 3) and 95.63 ± 4.42 (n = 3), respectively. Kinetics for the stability study was performed.

Determination of lamotrigine in human serum by high-performance liquid chromatography–tandem mass spectrometry

A rapid and sensitive liquid chromatography–tandem mass spectrometry method was developed and validated for quantification of lamotrigine in human serum. After a simple protein precipitation using acetonitrile, the analytes were separated on a Shideido 150 mm × 2.0 mm, 5 μm Capcell Pak C18 MG column using 70% acetonitrileas mobile phase at a flow rate of 200 μl/min. Lamotrigine was eluted at 1.98 min, ionized using electrospray ionization source, and then detected by multiple reaction monitoring mode. The precursor to product ion transitions of m/z 256.1–109.0 was used to quantify. The analytical measurement range is from 0.1 to 20 μg/ml and the upper clinical reportable range is chosen to be 100 μg/ml. The method was successfully employed in a clinical application.

Development and Validation of a Rapid Column-Switching High-Performance Liquid Chromatographic Method for the Determination of Lamotrigine in Human Serum

This study describes a simple and sensitive column-switching high-performance liquid chromatographic method with UV detection for the determination of Lamotrigine in 50 microL of serum. After solid-phase extraction of Lamotrigine on an Oasis HLB extraction precolumn (20 x 3.9 mm; dp: 25 microm), chromatographic separation was achieved at 30 degrees C on a Chromolith RP-18e column (50 mm x 4.6 mm i.d.) using a solution of 20% acetonitrile in 15 mM phosphate buffer (pH 7.0) as the mobile phase, at a flow-rate of 2.0 mL/min. The eluant was detected at 215 nm. The retention time for Lamotrigine was 1.28 min. The total analysis time was ca. 5 min. However, the overlap of sample preparation, analysis, and reconditioning of the precolumn increased the overall sample throughput to one injection every 3 min. The method was validated for system suitability, linearity, precision, accuracy, robustness, and limit of quantitation. The linearity of the calibration lines, expressed by the linear correlation coefficient, was better than 0.9996. Recovery studies achieved from Lamotrigine spiked plasma samples showed values greater than 93%, demonstrating the excellent extraction efficiency of the precolumn. Intra- and inter-day precision were generally acceptable; the coefficient of variation was < 2.3% in all cases. The detection limits for Lamotrigine at a signal-to-noise ratio of 3 was 0.002 microg/mL when a sample volume of 50 microL was injected. However, it was possible to enhance the sensitivity further by injecting larger volumes, up to 200 microL. The method was shown to be robust and the results were within the acceptable range. The method was successfully applied to the determination of Lamotrigine in human serum samples of patients submitted to Lamotrigine therapy.

Determination of Lamotrigine in Pharmaceutical Preparations by Adsorptive Stripping Voltammetry Using Screen Printed Electrodes.

This paper describes a procedure that has been optimized for the determination of lamotrigine by Differential Pulse Adsorptive Stripping Voltammetry (DPAdSV) using carbon screen-printed electrodes (CSPE) and mercury coated carbon screen-printed electrodes. Selection of the experimental parameters was made using experimental design methodology. The detection limit found was 5.0 × 10-6 M and 2.0 × 10-6 M for the non modified and Hg modified CSPE, respectively. In terms of reproducibility, the precision of the above mentioned methods was calculated in %RSD values at 9.83% for CSPE and 2.73% for Hg-CSPE. The Hg-coated CSPEs developed in this work were successfully applied in the determination of lamotrigine in pharmaceutical preparations.

Development and Validation of a HPLC Method for a Dissolution Test of Lamotrigine Tablets and its Application to Drug Quality Control Studies

A high performance liquid chromatographic (HPLC) method suitable for routine determination of lamotrigine in a dissolution medium and tablet formulation has been developed. Chromatographic separation was performed on a Gemini C18 (250 mm×4.6 mm i.d., 5 µm) column using a mobile phase of 0.05 M (NH4)H2PO4‐acetonitrile (68∶32, v/v, pH 2.68), delivered at a flow rate of 1.2 mL/min and detected by ultraviolet at 265 nm. The method was validated for specificity, linearity, accuracy, and precision. Additionally, the conditions of the dissolution test for lamotrigine tablets were presented by using: paddle at 50 rpm stirring speed; medium volume of 900 mL; temperature at 37±0.5°C; and pH 1.2 HCl solution, pH 4.5 acetate buffer and pH 6.8 phosphate buffer as dissolution media. The proposed analytical and dissolution methods were applied successfully for the quality control of commercial lamotrigine tablets and the comparison of in vitro performances of their products.